Patients with a specific type of bowel cancer who were treated with a short course of immunotherapy before surgery instead of post-op chemotherapy have remained cancer-free after almost three years of follow-up, according to new results from the NEOPRISM-CRC clinical trial led by a team from UCL and UCLH.
Scientists created MitoCatch, a method to send healthy mitochondria directly to specific damaged cells. This is important because mitochondrial issues are linked to diseases like Parkinson’s, Alzheimer’s, and heart failure, and current approaches can’t target the right cells well.
In tests, the delivered mitochondria worked normally inside cells and improved survival of damaged neurons and eye cells without triggering immune reactions. It’s an early but promising step toward more precise treatments that fix cell energy problems at the source.